reported in The Lancet is therefore highly welcomed. Previously, a smaller randomised controlled trial showed a non-significant reduction in maternal adverse outcomes if late preterm pre-eclampsia was ended before term, 9 and a recent individual participant data meta-analysis found a likely maternal benefit to delivery before gestational week 37. 10 Chappell and colleagues determined in their appropriately powered PHOENIX trial (protocol published previously) 11 that planned delivery within the subsequent 48 h after randomisation in women with late preterm pre-eclampsia reduced severe maternal adverse outcomes without substantially worsening neonatal outcomes compared with the current practice of expectant management until 37 weeks' gestation. However, the planned delivery group did have a higher occurrence of neonatal unit referrals, in line with expected clinical challenges associated with neonatal lung immaturity. It was, however, reassuring that the frequency of true neonatal morbidities was not increased for this planned delivery group. Women in the expectant management group had a median of 5 days additional prolongation of pregnancy, yet more than half of them delivered before 37 weeks' gestation, with three-quarters progressing to severe forms of preeclampsia. The planned delivery group had a higher rate of vaginal deliveries compared with the expectant management group, which has positive implications for future obstetric history, including less risk for uterine ruptures and invasive placentas. Furthermore, the total health costs of planned delivery were lower than for expectant management in this UK setting, in line with the shorter observation time for predelivery, less severe maternal morbidities, and no increase in neonatal morbidity. Chappell and colleagues' wisely suggest shared decision making with late preterm pre-eclamptic women (34-37 weeks' gestation), offering initiation of delivery with the aim of reducing maternal morbidity and severe hypertension, balanced against the increased risk of neonatal unit admissions, albeit without increasing newborn respiratory or other morbidities.
Women with a history of pre-eclampsia are at increased risk for several non-communicable disorders, including cardiovascular disease. The associations strengthen with repeated pre-eclampsia, fetal growth restriction, and preterm onset. 12 The mechanisms behind these associations are not clear. One theory, in addition to the shared risk theory, is that stress signals from the dysfunctional placenta to the maternal cardiovasculature might aggravate cardiovascular dysfunction and promote premature cardiovascular disease. 12 Initiating delivery in late preterm pre-eclampsia rather than waiting until term might theoretically reduce the stress on the woman's cardiovasculature. Whether a change to active delivery of women with late preterm preeclampsia will also benefit maternal cardiovascular health in the long term should be addressed in future follow-up studies.
The PHOENIX trial 8 findings are likely to be generalisable to similar health-care settings. A more active delivery procedure in late preterm pre-eclampsia would probably be beneficial in other high and middle income countries that have a high level of care available to preterm infants with immaturity challenges. In low-income settings without adequate pregnancy, delivery, and neonatal follow-up, the risks to the premature infant must be weighed against the reduction in adverse maternal outcomes before recommending active delivery over expectant surveillance for the late preterm pre-eclampsia group. The high global rates of maternal and fetal deaths due to pre-eclampsia are unacceptable. Access to adequate antenatal and delivery care in low-income settings is essential to prevent deaths and to improve maternal and offspring health outcomes globally.
